Urgent New Alert: About Coming Once-in-a-generation Wealth Shift
Here is the latest financial fact sheet of STRIDES PHARMA SCIENCE. For more details, see the STRIDES PHARMA SCIENCE quarterly results and STRIDES PHARMA SCIENCE share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 1.9 |
No. of shares | m | 59.65 |
% ch week | % | 1.5 |
% ch 1-mth | % | -0.4 |
% ch 12-mth | % | 166.0 |
52 week H/L | Rs | 1,000.0/322.0 |
No. of Mths Year Ending |
15 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
---|
STRIDES PHARMA SCIENCE EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 1,138 | 1,199 | 1,413 | 1,275 | 1,147 | |
Low | Rs | 344 | 384 | 848 | 918 | 642 | |
Sales per share (Unadj.) | Rs | 225.1 | 200.6 | 320.3 | 308.1 | 317.2 | |
Earnings per share (Unadj.) | Rs | 296.6 | 141.7 | 13.2 | 31.3 | 7.8 | |
Diluted earnings per share | Rs | 296.2 | 141.7 | 19.8 | 46.9 | 11.8 | |
Cash flow per share (Unadj.) | Rs | 306.1 | 152.5 | 27.9 | 45.4 | 25.1 | |
Dividends per share (Unadj.) | Rs | 505.00 | 108.00 | 5.00 | 4.50 | 2.00 | |
Adj. dividends per share | Rs | 504.32 | 107.95 | 7.49 | 6.75 | 3.00 | |
Dividend yield (eoy) | % | 68.2 | 13.7 | 0.4 | 0.4 | 0.2 | |
Book value per share (Unadj.) | Rs | 169.0 | 193.9 | 297.5 | 307.4 | 274.3 | |
Adj. book value per share | Rs | 168.8 | 193.8 | 445.6 | 460.8 | 411.5 | |
Shares outstanding (eoy) | m | 59.57 | 59.62 | 89.35 | 89.42 | 89.50 | |
Bonus/Rights/Conversions | ESOP | ESOP | ESOP | ESOP | ESOP | ||
Price / Sales ratio | x | 3.3 | 3.9 | 3.5 | 3.6 | 2.8 | |
Avg P/E ratio | x | 2.5 | 5.6 | 85.5 | 35.1 | 114.0 | |
P/CF ratio (eoy) | x | 2.4 | 5.2 | 40.5 | 24.2 | 35.7 | |
Price / Book Value ratio | x | 4.4 | 4.1 | 3.8 | 3.6 | 3.3 | |
Dividend payout | % | 170.3 | 76.2 | 37.8 | 14.4 | 25.5 | |
Avg Mkt Cap | Rs m | 44,135 | 47,165 | 100,988 | 98,036 | 80,058 | |
No. of employees | `000 | 1.5 | 2.0 | 4.7 | 5.8 | 2.5 | |
Total wages/salary | Rs m | 1,572 | 1,721 | 3,577 | 4,192 | 4,341 | |
Avg. sales/employee | Rs Th | 8,939.5 | 5,979.3 | 6,102.8 | 4,750.8 | 11,325.8 | |
Avg. wages/employee | Rs Th | 1,047.9 | 860.3 | 762.7 | 722.7 | 1,731.4 | |
Avg. net profit/employee | Rs Th | 11,778.3 | 4,225.0 | 251.9 | 482.2 | 280.1 |
STRIDES PHARMA SCIENCE INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 13,409 | 11,959 | 28,622 | 27,554 | 28,394 | |
Other income | Rs m | 602 | 386 | 921 | 1,611 | 941 | |
Total revenues | Rs m | 14,012 | 12,344 | 29,543 | 29,165 | 29,334 | |
Gross profit | Rs m | 2,234 | 2,289 | 4,140 | 5,274 | 3,965 | |
Depreciation | Rs m | 565 | 640 | 1,313 | 1,262 | 1,540 | |
Interest | Rs m | 1,089 | 474 | 1,682 | 1,831 | 1,962 | |
Profit before tax | Rs m | 1,183 | 1,560 | 2,067 | 3,792 | 1,403 | |
Minority Interest | Rs m | -6 | 6 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | -47 | 4 | -168 | |
Extraordinary Inc (Exp) | Rs m | 19,736 | 8,361 | -414 | -364 | -436 | |
Tax | Rs m | 3,245 | 1,476 | 425 | 634 | 97 | |
Profit after tax | Rs m | 17,667 | 8,450 | 1,181 | 2,797 | 702 | |
Gross profit margin | % | 16.7 | 19.1 | 14.5 | 19.1 | 14.0 | |
Effective tax rate | % | 274.3 | 94.6 | 20.5 | 16.7 | 6.9 | |
Net profit margin | % | 131.8 | 70.7 | 4.1 | 10.2 | 2.5 |
STRIDES PHARMA SCIENCE BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 13,086 | 14,447 | 35,149 | 37,918 | 24,836 | |
Current liabilities | Rs m | 7,074 | 10,022 | 18,920 | 31,039 | 18,993 | |
Net working cap to sales | % | 44.8 | 37.0 | 56.7 | 25.0 | 20.6 | |
Current ratio | x | 1.8 | 1.4 | 1.9 | 1.2 | 1.3 | |
Inventory Days | Days | 48 | 63 | 78 | 97 | 71 | |
Debtors Days | Days | 99 | 112 | 132 | 132 | 113 | |
Net fixed assets | Rs m | 5,506 | 8,400 | 35,682 | 37,639 | 34,289 | |
Share capital | Rs m | 596 | 596 | 894 | 894 | 895 | |
"Free" reserves | Rs m | 4,594 | 10,962 | 25,685 | 26,594 | 23,651 | |
Net worth | Rs m | 10,068 | 11,558 | 26,579 | 27,488 | 24,546 | |
Long term debt | Rs m | 2,755 | 2,530 | 26,270 | 16,377 | 15,513 | |
Total assets | Rs m | 20,990 | 24,805 | 74,559 | 81,050 | 65,437 | |
Interest coverage | x | 2.1 | 4.3 | 2.2 | 3.1 | 1.7 | |
Debt to equity ratio | x | 0.3 | 0.2 | 1.0 | 0.6 | 0.6 | |
Sales to assets ratio | x | 0.6 | 0.5 | 0.4 | 0.3 | 0.4 | |
Return on assets | % | 89.4 | 36.0 | 3.8 | 5.7 | 4.1 | |
Return on equity | % | 175.5 | 73.1 | 4.4 | 10.2 | 2.9 | |
Return on capital | % | 171.6 | 73.8 | 6.2 | 12.0 | 6.9 | |
Exports to sales | % | 59.4 | 60.2 | 53.1 | 0 | 0 | |
Imports to sales | % | 20.5 | 23.5 | 15.9 | 0 | 0 | |
Exports (fob) | Rs m | 7,959 | 7,204 | 15,192 | 0 | 0 | |
Imports (cif) | Rs m | 2,752 | 2,809 | 4,565 | 0 | 0 | |
Fx inflow | Rs m | 22,791 | 13,031 | 16,612 | 13,465 | 15,697 | |
Fx outflow | Rs m | 3,088 | 3,165 | 5,292 | 4,076 | 735 | |
Net fx | Rs m | 19,703 | 9,865 | 11,320 | 9,389 | 14,962 |
STRIDES PHARMA SCIENCE CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | -2,717 | 834 | 733 | 2,881 | 1,871 | |
From Investments | Rs m | 40,771 | 519 | -22,248 | -6,867 | 5,826 | |
From Financial Activity | Rs m | -33,185 | -4,213 | 29,439 | 3,382 | -10,157 | |
Net Cashflow | Rs m | 4,869 | -2,860 | 7,924 | -603 | -2,615 |
Share Holding
|
Company Information
|
CHM: Deepak Vaidya (MD) | COMP SEC: Badree Komandur (EVP-Finance) | YEAR OF INC: 1980 | BSE CODE: 532531 | FV (Rs): 10 | DIV YIELD (%): 0.3 |
Read: STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: SHASUN PHARMA PFIZER INDRAPRASTHA MEDICAL TTK HEALTHCARE ORCHID PHARMA
Compare STRIDES PHARMA SCIENCE With: SHASUN PHARMA PFIZER INDRAPRASTHA MEDICAL TTK HEALTHCARE ORCHID PHARMA
Compare STRIDES PHARMA SCIENCE With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More